Related Experiment Video

Updated: Jun 7, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Targeting RSK2 in human malignancies

Sumin Kang1, Jing Chen

  • 1Emory University School of Medicine, Winship Cancer Institute of Emory, Department of Hematology and Medical Oncology, Atlanta, GA 30322, USA. smkang@emory.edu; jchen@emory.edu

Expert Opinion on Therapeutic Targets
|October 26, 2010
PubMed
Abstract

Insights

p90 ribosomal S6 kinase 2 (RSK2) is vital in cancer progression. Targeting RSK2 offers a promising therapeutic strategy for various human malignancies, with its effectiveness depending on specific cancer types and cellular environments.

Area of Science:

  • Molecular biology
  • Oncology
  • Biochemistry

Background:

  • p90 ribosomal S6 kinase 2 (RSK2) is a Ser/Thr kinase involved in cell cycle, survival, and proliferation.
  • RSK2 plays a critical role in oncogenesis and tumor progression, identifying it as a key therapeutic target.

Purpose of the Study:

  • To review the role of RSK2 in human cancers, including hematopoietic malignancies and solid tumors.
  • To discuss the therapeutic implications of targeting RSK2 in clinical settings.

Main Methods:

  • Review of recent findings on RSK2's role in human cancers.
  • Analysis of therapeutic strategies targeting RSK2.

Main Results:

  • RSK2 activation mechanisms and its contribution to human cancers are elucidated.
  • Insights into developing novel targeted cancer therapies are provided.

Conclusions:

  • RSK2's significance in cancer varies across malignancies, influenced by oncogene signaling and tumor microenvironment.
  • Further research into RSK2 signaling and its interactions is crucial for effective cancer therapeutics.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...